Silk Road Medical Inc: insider trades · United States · SEC (Form 4)

About Silk Road Medical Inc

Silk Road Medical Inc. (ticker: SILK) was a US medical-device company listed on the NASDAQ market in the United States. Founded in 2007 and incorporated in Delaware, the company built its business around a highly focused mission: reducing stroke risk in patients with carotid artery disease. Its historic headquarters was in Sunnyvale, California, with an additional operational presence in Plymouth, Minnesota. The company’s core franchise centered on transcarotid artery revascularization, or TCAR, a minimally invasive procedure that combines surgical neuroprotection principles with endovascular techniques to treat carotid artery blockages. Silk Road Medical commercialized and supported this approach through its ENROUTE product platform and related accessories used in TCAR procedures. In business-model terms, it operated as a specialized med-tech manufacturer with a clinical and sales infrastructure aimed at hospitals, vascular surgeons, and stroke-prevention centers. From a competitive standpoint, Silk Road Medical’s key differentiator was not diversification, but depth in a single clinically important niche. That focus gave the company a recognizable identity in carotid disease treatment and allowed it to expand the adoption of TCAR through evidence generation, reimbursement support, physician education, and commercial execution. For investors, this specialization was both an advantage and a concentration risk: growth depended heavily on continued TCAR uptake, favorable clinical acceptance, and reimbursement dynamics rather than on a broad product portfolio. Recent developments were material. In early 2024, the company reported revenue growth driven by continued TCAR adoption and highlighted commercial progress. Later in 2024, Silk Road Medical announced that it was moving toward an acquisition by Boston Scientific, and it withdrew its full-year 2024 guidance in connection with that proposed transaction. SEC filings and earnings releases indicate that the company continued operating and reporting results through the deal process before the transaction was completed. For French-, Belgian-, and Swiss-based investors, Silk Road Medical should therefore be viewed as a specialized US med-tech platform that transitioned from an independent NASDAQ-listed company into part of a larger strategic healthcare group.